These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26805904)

  • 1. Laboratory monitoring of new hemostatic agents for hemophilia.
    Pruthi RK
    Semin Hematol; 2016 Jan; 53(1):28-34. PubMed ID: 26805904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice.
    Sarafanov AG
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies.
    Kitchen S; Tiefenbacher S; Gosselin R
    Semin Thromb Hemost; 2017 Apr; 43(3):331-337. PubMed ID: 28264199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients.
    Yu JK; Iorio A; Edginton AN
    Thromb Res; 2020 Dec; 196():550-558. PubMed ID: 33157394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management.
    Müller J; Goldmann G; Marquardt N; Pötzsch B; Oldenburg J
    Hamostaseologie; 2020 Nov; 40(S 01):S15-S20. PubMed ID: 33187006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A.
    Abdelgawad HAH; Foster R; Otto M
    Blood Rev; 2024 Mar; 64():101164. PubMed ID: 38216442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement.
    Van den Bossche D; Peerlinck K; Jacquemin M
    Int J Lab Hematol; 2018 May; 40 Suppl 1():21-29. PubMed ID: 29741261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B.
    Abraham S; Duncan EM
    Methods Mol Biol; 2023; 2663():569-588. PubMed ID: 37204737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products.
    Berntorp E; Andersson NG
    Semin Thromb Hemost; 2016 Jul; 42(5):518-25. PubMed ID: 27096762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.
    Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
    J Pharm Sci; 2015 Feb; 104(2):388-95. PubMed ID: 24700333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibody mimicking factor VIII.
    Nogami K
    Thromb Res; 2016 May; 141 Suppl 2():S34-5. PubMed ID: 27207420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays.
    Peyvandi F; Kenet G; Pekrul I; Pruthi RK; Ramge P; Spannagl M
    J Thromb Haemost; 2020 Jun; 18(6):1242-1255. PubMed ID: 32115865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long and short of it: using the new factor products.
    Dunn A
    Hematology Am Soc Hematol Educ Program; 2015; 2015():26-32. PubMed ID: 26637697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2017 Clinical trials update: Innovations in hemophilia therapy.
    Hartmann J; Croteau SE
    Am J Hematol; 2016 Dec; 91(12):1252-1260. PubMed ID: 27563744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis.
    Carcao M; Lambert T; Leissinger C; Escuriola-Ettingshausen C; Santagostino E; Aledort L;
    Haemophilia; 2018 Nov; 24(6):845-848. PubMed ID: 29989273
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Congenital hemophilia: a new treatment paradigm].
    Shima M
    Rinsho Ketsueki; 2019; 60(6):647-658. PubMed ID: 31281158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
    Gray E; Kitchen S; Bowyer A; Chowdary P; Jenkins PV; Murphy P; Platton S; Riddell A; Lester W
    Haemophilia; 2020 Jan; 26(1):6-16. PubMed ID: 31846168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current developments in hemostatic treatment for patients with hemophilia].
    Nogami K
    Rinsho Ketsueki; 2021; 62(8):1213-1221. PubMed ID: 34497209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.